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The human APOBEC3G protein exhibits broad antiretroviral activity against a variety of retroviruses. It is packaged into viral particles
and executes its antiviral function in the target cell. The packaging of APOBEC3G into different viral particles requires a mechanism that
confers this promiscuity. Here, APOBEC3G incorporation into murine leukemia virus (MLV) was studied using retroviral vectors.
APOBEC3G uptake did not require either its cytidine deaminase activity or the presence of a retroviral vector genome. Results from
immunoprecipitation and co-localization studies of APOBEC3G with a MLV Gag–CFP (cyan fluorescent protein) fusion protein imply an
interaction between both proteins. RNase A treatment did not inhibit the co-precipitation of Gag–CFP and APOBEC3G, suggesting that the
interaction is RNA independent. Like human immunodeficiency virus (HIV) Gag, the MLV Gag precursor protein appears to interact with
APOBEC3G, indicating that Gag contains conserved structures which are used to encapsidate APOBEC3G into different retroviral particles.
D 2005 Elsevier Inc. All rights reserved.Keywords: APOBEC3G; MLV; Vif; Retroviral vectorIntroduction
The human cytidine deaminase APOBEC3G (CEM15) is
an antiviral host factor that restricts replication of retro-
viruses (Mangeat et al., 2003; Sheehy et al., 2003) and
hepadnaviruses (Turelli et al., 2004). APOBEC3G function
has been mainly studied in the context of human immuno-
deficiency virus (HIV) infection. In the absence of the HIV
Vif (viral infectivity factor) protein, APOBEC3G deami-
nates dC to dU in the first-strand cDNA intermediate of the
reverse transcription reaction (Marin et al., 2003). This
results in a severe reduction in functional viral genomes
integrated into host cells and impairs viral replication. The
HIV-1 accessory protein Vif is required by HIV for
replication in non-permissive cells, such as primary T cells,
which express APOBEC3G. Vif-deficient HIV variants and
murine leukemia virus (MLV), which does not encode Vif or
a functional homolog, incorporate APOBEC3G into viral0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.04.006
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E-mail address: schba@pei.de (B.S. Schnierle).particles. The outcome is the delivery of the mutagen to the
target cell, making it available to act on the viral cDNA.
MLV has been described to be resistant to the murine
homologue of APOBEC3G, which explains the absence of a
Vif-like activity in MLV (Kobayashi et al., 2004). Vif
neutralizes APOBEC3G by preventing its encapsidation
into HIV virions by a mechanism that is not entirely
understood. It has been suggested that Vif induces the
ubiquitin-dependent degradation of APOBEC3G (Marin et
al., 2003; Rose et al., 2004; Yu et al., 2003) and/or Vif
affects the translation of APOBEC3G (Kao et al., 2003;
Stopak et al., 2003).
The mechanism of APOBEC3G incorporation into
retroviral particles is also not well understood. It has been
suggested that APOBEC3G is encapsidated by direct
interaction with the HIV Gag precursor protein (Alce and
Popik, 2004; Cen et al., 2004; Douaisi et al., 2004), the
nucleocapsid (NC) (Luo et al., 2004) or RNA (Schafer et al.,
2004; Svarovskaia et al., 2004; Zennou et al., 2004). Given
that APOBEC3G affects distantly related retroviruses, its
packaging should involve a common mechanism. We have
studied the incorporation of APOBEC3G into MLV vector05) 175 – 182
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interaction with MLV Gag and does not require the presence
of genomic RNA.Results
The cytidine deaminase activity of APOBEC3G is required
to reduce retroviral vector titers
We analyzed the consequence of APOBEC3G expression
on MLV infectivity using MLV-based retroviral vectors.
Vectors were transiently produced in 293T cells, either in the
presence or absence of APOBEC3G expression. Infectivity
of the vectors was monitored by transduction of a retroviral
vector genome encoding the green fluorescent protein (GFP)
into NIH3T3 cells. In addition to wild-type (wt) APO-
BEC3G, we used an APOBEC3G variant carrying a single
amino acid exchange at position 259 (APO-E259Q). This
mutation affects the conserved zinc binding domain (H-X-
E-(X)24-30-PCXXC) found in the active site of all cytidine
deaminases and the mutated glutamate is involved in proton
shuttling (Jarmuz et al., 2002). Two aromatic residues in this
(X)24-30 domain are predicted to be involved in RNA-
binding (Jarmuz et al., 2002). Although not experimentally
shown here, it is very unlikely that RNA binding is affected
by the E259Q mutation. It has been previously described to
have almost completely lost its antiviral effect on HIV
infectivity due to impaired cytidine deaminase activity
(Shindo et al., 2003). Fig. 1 summarizes the titers obtained.
Titers obtained from vectors produced by co-transfection ofFig. 1. Retroviral vector titers determined by monitoring GFP-positive cells.
293T cells were transfected with 7 Ag pHIT60 (Gag/Pol), 3 Ag pEnv
wt(HX) (Env) 10 Ag pSFG-EGFP (vector encoding GFP) and 5 Ag
pcDNA–APOBEC3G–Myc (APOBEC3G), pcDNA–E259Q (APO–
E259Q) or pRC–CMV (empty vector as control) expression plasmids
using a standard calcium phosphate precipitation technique. Trans-
ductions were carried out by incubating NIH3T3 target cells for 2 days
with 1 ml, 100 Al and 10 Al of supernatants from transfected 293T cells
containing retroviral particles. Viral titers were determined from the
percentage of GFP-positive cells. The titers are expressed in infectious
units per ml (IU/ml).the empty expression plasmid (pRC-CMV) were set to
100%. In the presence of an APOBEC3G expression vector,
the titer declined to 7.8%. The APOBEC3G variant APO-
E259Q, however, only slightly interfered with the trans-
duction rate (78%) indicating that, in agreement with
previous observation with HIV, this mutant had lost its
antiviral activity against MLV.
APOBEC3G and APO-E259Q are incorporated into MLV
particles independently of vector mRNA
Encapsidation of APOBEC3G and APO-E259Q into
MLV-based vector particles was analyzed by Western blot
analysis. Viral particles were prepared from supernatants
of transfected 293T cells by ultracentrifugation through a
30% sucrose cushion. The human APOBEC3G gene was
expressed as a C-terminal fusion with the Myc-tag
(APOBEC3G-Myc), which enabled APOBEC3G detection
by an antibody directed against the Myc epitope (Marin
et al., 2003). APOBEC3G expression was first analyzed
in 293T cell lysates and equal gel loading was confirmed
by detection of h-actin (Fig. 2A). Analysis of viral
particles showed that both the wt and the mutant
APOBEC3G proteins were incorporated into particles
(Fig. 2B, lanes 1, 2 and 4, 5). Slight variations in the
amount of APOBEC3G protein detected were due to
loading differences, as indicated by levels of the MLV
capsid (CA) protein p30. APOBEC3G was encapsidated
in the absence of vector mRNA (Fig. 2B, lanes 2 and 5).
We next addressed whether co-expression of the HIV Vif
gene also affects APOBEC3G incorporation into MLV
particles. Retroviral vectors were produced in the
presence of APOBEC3G and HIV-1 Vif expression. The
co-expression of Vif diminished the amount of APO-
BEC3G in cell lysates (Fig. 2C, lane 1) and resulted in
its exclusion from MLV vector particles (Fig. 2D, lane
1). However, Vif expression during vector production
resulted in Vif incorporation into MLV particles, inde-
pendent of APOBEC3G co-expression, which might
result from overexpression of Vif (Fig. 2D, lanes 1 and
3). Vector titers were higher when Vif was co-expressed:
transduction rates in the presence of APOBEC3G alone
were only 35% of those obtained in the additional
presence of Vif (data not shown). This indicates that
Vif also restored APOBEC3G-restricted MLV infectivity.
MLV Gag partially co-localizes with APOBEC3G and can
be co-precipitated with APOBEC3G
Packaging of APOBEC3G into HIV particles is mediated
by the Gag protein (Alce and Popik, 2004; Cen et al., 2004;
Luo et al., 2004; Schafer et al., 2004; Svarovskaia et al.,
2004; Zennou et al., 2004) and an interaction of APO-
BEC3G with MLV Gag has recently been observed
following overexpression of both proteins by vaccinia
virus-expressed T7 polymerase (Douaisi et al., 2004). We
Fig. 2. APOBEC3G incorporation into MLV particles. (A) Western blot analysis of transfected 293T cells lysates. The amount of expression plasmid used for
transfections is indicated in Ag. The APOBEC3G protein was detected via its Myc-tag with an anti-Myc antibody and equal loading was analyzed, after
stripping the blot, with an antibody directed against h-actin. (B) Western blot analysis of viral particles obtained by ultracentrifugation of cell culture
supernatants from transfected 293T cells. The APOBEC3G protein was detected via its Myc-tag with an anti-Myc antibody and equal loading was analyzed,
after stripping the blot, with an antibody directed against the MLV Gag p30 CA protein. (C) Western blot analysis of transfected 293T cells lysates. The amount
of expression plasmid used for transfections is indicated in Ag. The APOBEC3G-Myc protein was detected with an anti-Myc antibody, Vif was detected with an
anti-Vif antibody and equal loading was analyzed, after stripping the blot, with an antibody directed against h-actin. (D) Western blot analysis of viral particles
obtained by ultracentrifugation of cell culture supernatants from transfected 293T cells. The APOBEC3G-Myc protein was detected with an anti-Myc antibody,
Vif with an anti-Vif antibody and equal loading was analyzed, after stripping the blot, with an antibody directed against the MLV Gag p30 CA protein. Vif was
detected after running an additional SDS-PAGE and Western blot analysis with twice the amount of viral particles as that used for APOBEC3G and Gag.
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by using a Gag expression plasmid encoding a chimeric Gag
molecule which had the cyan fluorescent protein (CFP)
fused to the C terminus of the NC domain. Expression of
this construct leads to the formation of fluorescently labeled,
non-infectious viral particles (generous gift of M. Collins
and Y. Takeuchi) (Andrawiss et al., 2003). This fusion
protein has been used previously to detect particle produc-
tion by measuring fluorescence. Gag–CFP protein releases
virus-like particles upon transfection into 293T cells, which
are detectable by microscopy as fluorescent spots (Andra-
wiss et al., 2003) (Fig. 3B). Plasmids encoding APO-
BEC3G-Myc and Gag–CFP were transfected into 293T
cells. After 2 days, cells were fixed, stained with an anti-
Myc antibody (9E10) and analyzed by confocal laser
scanning microscopy. APOBEC3G expression could be
detected in the cytoplasm (Fig. 3A) and Gag–CFP showed
cytoplasmic and dotted membrane staining (Fig. 3B). Some
of the Gag–CFP spots were enriched with APOBEC3G,
appearing as white dots in the overlay in Fig. 3D (indicated
by arrows).
We further studied the interaction of APOBEC3G with
MLV Gag. After transfection of APOBEC3G-Myc andGag–CFP or wt Gag (pHIT60) expression plasmids into
293T cells, viral particles were harvested by ultracentrifu-
gation and the material was analyzed by Western blot.
Particle formation was analyzed by detection of Gag–CFP
using an anti-GFP antibody or detection of Gag using an
anti-p30 CA antibody (Fig. 4A). In addition, APOBEC3G-
Myc was immunoprecipitated from pelleted viral particles
with an antibody directed against the Myc epitope. The
precipitated material was analyzed by Western blot using
an anti-GFP or an anti-p30 CA antibody. Gag is usually
cleaved by the viral protease into matrix (MA), CA and
NC (Fig. 4A, lane 2), however, the Gag–CFP protein
remains as a precursor and is not cleaved (Andrawiss et
al., 2003) (Fig. 4A, lanes 1 and 4). Co-precipitation of
Gag–CFP with APOBEC3G could be observed (Fig. 4B,
lane 1) and interaction with wt Gag precursor and CA p30
could be observed after longer exposure of the Western
blot (Fig. 4B, lanes 2 and 5). A minor background binding
of the Gag–CFP precursor protein to the beads alone
could be observed (Fig. 4B, lane 4); however, the
interaction was always more prominent in the presence
of APOBEC3G, indicating that this protein interacts with
MLV Gag components.
Fig. 4. Co-immunoprecipitation of Gag–CFP with APOBEC3G. Virus-like parti
presence or absence of APOBEC3G–Myc. The plasmid amount is given in Ag. Vir
(A) Detection of Gag either with an antibody directed against GFP to identify the
protein is not cleaved by the viral protease (lanes 1 and 4) unlike the wt Gag prote
an anti-Myc antibody. Gag–CFP in the precipitate was detected with an anti-G
APOBEC3G–Myc allowed the co-precipitation of Gag–CFP and very low amou
Fig. 3. Co-localization of APOBEC3G and Gag–CFP. The Gag–CFP
expression plasmid, encoding a chimeric Gag molecule containing CFP
fused to the C terminus of the NC domain and the APOBEC3G–Myc
fusion constructs were transfected in equal amounts into 239T cells. Cells
were fixed with methanol/acetone (1/1) and incubated with an anti-Myc
antibody, followed by an R-PE-labeled anti-mouse antibody. Cells were
examined with a Zeiss Laser-Scanning Microscope LSM510 equipped with
a 63 objective. Enhanced cyan fluorescent protein (ECFP) was excited
with a krypton 413 laser line and R-PE was excited with a HeNe 543 laser
line. (A) APOBEC3G, (B) Gag–CFP, (C) bright field, (D) overlay.
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is not affected by RNase A treatment
We have shown that APOBEC3G is incorporated into
MLV vector particles in the absence of a viral genome
(Fig. 2B), suggesting that APOBEC3G incorporation does
not require viral genomic RNA. Therefore, the interaction
of Gag–CFP and APOBEC3G was analyzed in the
presence or absence of 1 mg/ml RNase A (Qiagen, Hilden,
Germany). APOBEC3G-Myc, Gag–CFP and a retroviral
vector encoding GFP or an empty expression plasmid
(pRC-CMV) were transfected into 293T cells and viral
particles were concentrated by ultracentrifugation 3 days
later. Particle formation was confirmed by Western blot
analysis using an anti-GFP antibody (Fig. 5A). APO-
BEC3G-Myc was immunoprecipitated from these viral
particles using an anti-Myc antibody. The samples were
divided into two equal groups, one of which was treated
with RNase A during the immunoprecipitation procedure.
Western blot analysis confirmed immunoprecipitation of
APOBEC3G-Myc from viral particles (Fig. 5B, lower
band) and Gag–CFP could be co-immunoprecipitated from
samples containing APOBEC3G-Myc. Neither the pre-
sence of the vector RNA (Fig. 5C compare lanes 1 and 5
with 4 and 8) nor the treatment with RNase A (Fig. 5C,
lanes 5 and 8) influenced the co-immunoprecipitation of
Gag–CFP. This indicates that the interaction of APO-
BEC3G with MLV Gag is RNA-independent or onlycles were generated by transfection of Gag/Pol expression plasmids in the
al particles were prepared as described before and analyzed by Western blot.
Gag–CFP fusion protein or with an anti-p30 CA antibody. The Gag–CFP
in (lane 2). (B) Viral particles were also used for immunoprecipitations with
FP antibody and p30 CA with an anti-p30 CA antibody. The presence of
nts of wt Gag, only detectable after longer exposure of the blot (lane 5).
Fig. 5. The APOBEC3G–Gag–CFP interaction is not affected by RNase A treatment. Virus-like particles were generated in 293T cells, purified by
ultracentrifugation and either directly analyzed for particle formation by Western blot analysis with an anti-GFP antibody (A) or used for immunoprecipitations
using an anti-Myc antibody. Successful immunoprecipitation was controlled by Western blot analysis of the precipitate with an anti-Myc antibody (B) and co-
precipitation of Gag–CFP was detected with an anti-GFP antibody (C).
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RNase A.
In addition, we verified the APOBEC3G/Gag–CFP
interaction in cell lysates of transfected 293T cells to
exclude that RNA is involved in the initial APOBEC3G/
Gag–CFP interaction in the cytoplasm, but not required
later in the viral particle. APOBEC3G-Myc was immuno-
precipitated from cell lysates and the samples were either
treated with RNase A or left untreated during the
immunoprecipitation procedure. As shown in Fig. 6, RNase
A did not significantly inhibit the APOBEC3G/Gag–CFP
interaction and the slightly lower amount of precipitated
Gag–CFP is due to loading differences (Figs. 6A, B, lanes 1
and 3). Due to unspecific binding of Gag–CFP to sepharoseFig. 6. The APOBEC3G–Gag–CFP interaction in cell lysates is not
affected by RNase A treatment. Cell lysates were generated from 293T cells
and either directly analyzed for Gag–CFP expression by Western blot
analysis with an anti-Gag antibody (C) or used for immunoprecipitations
using an anti-Myc antibody. Successful immunoprecipitation was con-
trolled by Western blot analysis of the precipitate with an anti-Myc antibody
(B) and co-precipitation of Gag–CFP was detected with an anti-Gag
antibody (A).beads, we had to use lower concentrations of RNase A with
cell lysates in contrast to viral particles, however, 1 Ag/ml
RNase A did not affect this interaction and indicates that
RNA is not essential for the APOBEC3G/Gag–CFP
interaction.Discussion
The effect of human APOBEC3G on MLV infection has
been controversially discussed. While some publications
have described a clear antiviral function (Harris et al., 2002;
Kobayashi et al., 2004; Mangeat et al., 2003), others did not
observe a strong inhibition of MLV infectivity by APO-
BEC3G (Mariani et al., 2003). Using MLV-based retroviral
vectors, we did observe a strong reduction of their
transduction efficiency in the presence of APOBEC3G.
An APOBEC3G variant with impaired deaminase activity
did not significantly interfere with vector transduction,
which further demonstrates that deaminase catalytic activity
is required to confer the antiretroviral effect of APOBEC3G.
The human APOBEC3G protein is incorporated into
HIV and MLV particles. We confirmed incorporation into
MLV particles and could further demonstrate that neither
APOBEC3G’s deaminase activity nor the presence of vector
RNA is required for packaging into MLV particles. To study
the encapsidation mechanism, we used a variant of the MLV
Gag precursor protein including an NC–CFP fusion protein
(Gag–CFP). This is not processed into the separate Gag
domains, but forms virus-like particles in the absence of
envelope protein and genomic RNA (Andrawiss et al.,
2003). Using confocal laser scanning microscopy and co-
immunoprecipitations, we observed that APOBEC3G inter-
acts with Gag–CFP. Co-localization was observed in
punctuated areas resembling budding viral particles. Co-
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the precursor protein Gag–CFP and a weak interaction
could be observed with wt Gag. This weak interaction with
wt Gag might be due to lower amounts of wt Gag protein in
293T cells (Fig. 4A, lane 2). The APOBEC3G–Gag–CFP
interaction resisted RNase A treatment, arguing for an
RNA-independent interaction. However, RNA has been
described to be essential for APOBEC3G binding to HIV
Gag (Schafer et al., 2004). The amino acid sequences of
retroviral Gag proteins have only a low degree of sequence
homology, and packaging of non-specific RNA by Gag as
well as APOBEC3G binding to RNA has been described
(Jarmuz et al., 2002). As APOBEC3G has been reported to
bind to RNA, binding to Gag via RNA cannot be entirely
excluded. However, all retroviral Gag precursor proteins are
organized in the same order, that is, MA, CA and NC. Gag
proteins share common features, for example, membrane
association and myristylation of MA. NC is highly
conserved among retroviruses. It contains zinc finger motifs
which are surrounded by basic regions and binds the
genomic RNA. These common functions make it a good
candidate for a ubiquitous interface and a direct binding of
APOBEC3G to the HIV NC domain has been described
(Cen et al., 2004).
Co-expression of APOBEC3G and Vif during MLV
vector production in 293T cells resulted in an elimination of
the APOBEC3G protein from cell lysates and, as expected,
its absence from viral particles. In addition, Vif expression
reversed the inhibitory effect of APOBEC3G on viral titers.
However, the experiments were carried out by overexpres-
sion of Vif in the presence of low amounts of APOBEC3G,
which might account for the absence of APOBEC3G protein
in cell lysates. Incomplete protein degradation of APO-
BEC3G by Vif has been described (Kao et al., 2004). We
also found Vif protein incorporated into MLV particles, an
observation described previously by others (von Schwedler
et al., 1993), which makes it tempting to speculate that
another Vif function might include masking a domain on
Gag that mediates the interaction with residual APOBEC3G
protein, however, this might as well only reflect an
unspecific uptake of Vif due to its overexpression.
APOBEC3G encapsidation into HIV and MLV particles
involves a common interaction with the Gag precursor
protein. The HIV Vif protein also interferes with the
antiviral function of APOBEC3G against MLV. This makes
MLV an attractive model system to be used to identify and
study inhibitors of the APOBEC3G–Vif interaction, which
could potentially be used in HIV therapy.Materials and methods
Plasmids
The following plasmids were used for transfections:
pcDNA–APOBEC3G–Myc encoding a C-terminallyMyc-tagged human APOBEC3G (Marin et al., 2003).
Gag–CFP was constructed based on the pHIT60 plasmid
(Soneoka et al., 1995) and the Pol coding region between
nucleotides 2235 and 5733 (corresponding to the Mo–
MLV sequence) was replaced by the CFP coding
sequences resulting in expression of Gag with a NC
CFP fusion protein (Andrawiss et al., 2003). Transfection
of this plasmid into 293T cells results in the production
of fluorescent, non-infectious particles. The plasmid
pHIT60 encodes the MLV Gag/Pol region (Soneoka et al.,
1995); pEnv wt(HX) encodes the ecotropic MLV enve-
lope protein (Erlwein et al., 2002); and pSFG–EGFP is a
MLV-based retroviral vector encoding GFP (Lindemann
et al., 1997). Transfection of pHIT60, pEnv wt (HX) and
pSFG–EGFP into 293T cells result in the production of
infectious vector particles, which are able to transduce the
GFP encoding vector sequences into target cells. PNL-
A1(CD4) encodes the HIV-1 Vif, Tat, Rev, Vpu and
Nef, allowing very high expression of Vif in 293T cells
(Willey et al., 1992).
The point mutation in the APOBEC3G coding
sequences (E259Q) was introduced using the Quick
Change Site-directed Mutagenesis Kit (Stratagene, Heidel-
berg), according to the manufacturer’s protocol and using
the oligonucleotides with the sequences Am-1: 5V-gcc gcc
atg cac agc tgt gct tcc and Am-2: 5V-gga agc aca gct gtg
cat ggc ggc. The variant was sequenced over the entire
coding region.
Cell culture, transfections, viral infection and determination
of titers
293T cells and NIH3T3 cells were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM; GIBCO/BRL, Eggen-
stein, Germany) supplemented with 10% fetal calf serum
(FCS; GIBCO/BRL, Eggenstein, Germany). A day before
transfection, 293T cells were seeded at a density of 3106
cells in a 10-cm tissue culture plate. The cells were
transfected with 10–20 Ag expression plasmids using a
standard calcium phosphate precipitation technique.
After 2 days of culture, serial dilutions of viral super-
natants from transfected 293T cells were passed through
0.45-Am filters (Greiner, Frickenhausen, Germany) and
incubated with 2105 NIH 3T3 cells. 48–72 h after
transduction, the numbers of GFP-expressing cells were
detected by FACS analysis. The titers are given in infectious
units per ml (IU/ml) and are the average of three
independent experiments.
Western blot analysis
Cell lysates were obtained and Western blot analyses
were performed as described previously (Schnierle et al.,
1996). Western blot analysis was performed with the
following antibodies: mouse anti-Myc antibody (BD-
Biosciences, Heidelberg, Germany), mouse anti-h-actin
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rabbit antiserum directed against MLV CA p30 (kind gift
of J. Schmidt, GSF, Munich, Germany), mouse anti-Vif
antibody (NIH AIDS Research and Reference Reagent
Program, #319), polyclonal rabbit antiserum directed
against GFP (BD-Biosciences-Clontech, Heidelberg, Ger-
many), which also recognizes CFP and horseradish
peroxidase-coupled sheep anti-mouse IgG antibodies or
protein A (Amersham Biosciences, Freiburg, Germany).
Detection was performed using an enhanced chemilumi-
nescence Western blot detection kit (Amersham Bioscien-
ces, Freiburg, Germany).
Isolation of viral particles
Two days after transfection of 293T cells with expres-
sion plasmids, the cell supernatants were filtered through a
0.45-Am filter and viral particles were pelleted through a
30% sucrose cushion for 90 min at 35,000 rpm in a SW41
rotor. Concentrated viral particles were analyzed by West-
ern blot as described for cell lysates or were used for
immunoprecipitations.
Immunoprecipitation
Viral particles, partially purified by ultracentrifugation,
were resuspended in 500 Al TNT buffer [20 mM Tris–HCl
(pH 7.5), 200 mM NaCl, 1% Triton X-100, 1 mM Pefabloc
(Roche, Mannheim, Germany)] and 2 Al anti-Myc-tag-
antibody (BD-Bioscience, Heidelberg, Germany) were
added and incubated for 2 h at 4 -C. Immune complexes
were collected with protein A/G-sepharose (Santa Cruz,
Biotechnology, Heidelberg, Germany) and washed three
times with TNT buffer. Bound proteins were eluted by
boiling in sample buffer and subjected to SDS-PAGE,
blotted onto nitrocellulose membranes and were subjected to
Western blot analysis.
Immunocytochemistry
Cells were fixed with methanol/acetone (1/1) and
APOBEC3G was detected after successive incubations
with an anti-Myc antibody and an R-PE-coupled goat
anti-mouse IgG antibody (DAKO, Hamburg, Germany).
Cells were examined with a Zeiss Laser-Scanning
Microscope LSM510 equipped with a  63 objective.
Enhanced cyan fluorescent protein (ECFP) was excited
with a krypton 413 laser line and R-PE was excited with
a HeNe 543 laser line.Acknowledgments
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